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patients with DLBCL in
Asia.
• A .500 mg absolute
dose of doxorubicin,
together with hyperten-
sion and history of as-
pirin use confer
a particularly high risk of
CVD incidence.
Evidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular
diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without
preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we
identified adults who were diagnosed with DLBCL and treated with chemotherapy between
2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart
disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative
incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric
competing risk analysis and adjusting for demographics, comorbidities, therapeutic
exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-
matched to DLBCL patients. We analyzed 2600 patients and 13000 controls. The adjusted
cause-specific hazard ratio (HR) for CVD in patients treated with .500 mg doxorubicin
compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74;
P 5 .013). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%,
4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; P 5
.082) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline
(HR, 2.13-4.63; P , .001 to .002) might confer a higher risk of subsequent CVDs. In this Hong
Kong population-based study, doxorubicin exposure (absolute dose.500 mg), together with
hypertension or baseline use of medication for cardiovascular risk factors, was found to be
associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying
CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients
are advisable.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma globally,
constituting 25% to 40% of all cases in different geographic regions.1-4 The median age at diagnosis is
;70 years.2 Effective modern therapeutic strategies have resulted in a 5-year survival exceeding 60%
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according to US population-based data.1 However, the therapeutic
exposures responsible for long-term survival are also implicated in
long-term sequelae among survivors. The mainstay of therapeutic
regimens for the treatment of patients with DLBCL includes rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone with or
without radiotherapy (RT).5 This anthracycline-based chemotherapy
regimen can increase the risk of cardiovascular sequelae; exposure
to chest RT and preexisting cardiovascular risk factors may also
further enhance the risk.6-19
However, to our knowledge, anthracycline-related cardiotoxicity has
not been studied in an Asian population diagnosed with DLBCL. It
has been well documented that the prevalence and management of
major cardiovascular risk factors can vary markedly worldwide.20
There are also significant differences in health habits and environ-
mental exposures among Asian populations compared with those in
theWestern world, which may influence the susceptibility ofWestern
populations to treatment-related cardiotoxicity.21-23 An improved
understanding of the interacting effects of preexisting comorbidities
and lifestyle factors on the relationship between DLBCL therapy
and cardiovascular diseases (CVDs) can guide upfront treatment
decisions as well as long-term cardiac risk–based survivorship care
tailored for this understudied population.
We aimed to determine the association between therapeutic
exposure (doxorubicin and RT) and new-onset CVD among DLBCL
survivors by analyzing population-based data, including information
on major cardiovascular risk factors, comorbidities, and lifestyle
factors in a population of DLBCL survivors and controls without
cancer in Hong Kong.
Materials and methods
Data sources
We retrieved data from the Clinical Data Analysis and Reporting
System (CDARS), an electronic medical database operated by
the Hong Kong Hospital Authority. The CDARS was established
in 1995 for audit and research purposes. The Hospital Authority is
the only public health care provider, and it covers ;90% of all
secondary and tertiary care in Hong Kong, which has a population
of nearly 7.5 million.24,25 Data on patient demographics, diagnoses,
hospitalizations, treatments, laboratory results, and causes, times,
and dates of death, are recorded in CDARS. In routine practice in
the Hong Kong Hospital Authority, clinicians in clinical and hospital
settings provide International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes for each episode
of attendance.26,27 In a previous study, these codes revealed a high
coding accuracy in diagnosing myocardial infarction and stroke with
positive predictive values of 85.4% (95% confidence interval [CI]
78.8%-90.6%) and 91.1% (95%CI, 83.2%-96.1%), respectively.28
Another study also demonstrated the reliability of the administrative
database of the Hong Kong Hospital Authority to capture
demographics and use of antidiabetic drugs with an almost
perfect level of data completeness regarding demographics
(100%) and drug prescription (99.98%).27 For other diagno-
ses, previous studies have also demonstrated high coding
accuracy, with positive and negative predictive values exceeding
90%.29,30 Patient confidentiality is protected by unique anonymous
identifiers that are linked to all data contained in the CDARS to
facilitate data retrieval. Various high-quality population-based
studies on CVDs, cancers, and medications have been published
based on data retrieved from the CDARS.28,31,32 The study protocol
was approved by the Research Ethics Committee of the New
Territories West Cluster, Hong Kong Hospital Authority (reference
no: NTWC/REC/19085).
Case definitions and outcome ascertainment
We used data from the CDARS to identify individuals histologically
diagnosed with DLBCL between 31 December 2018 and 1 January
2000. Figure 1 shows the study criteria and the final number of
patients who constituted the study cohort.33 The composite primary
outcome was incident CVD after DLBCL diagnosis, including
ischemic heart disease, heart failure, and cardiomyopathy clinically
diagnosed during inpatient hospital visits or as the cause of death
after lymphoma diagnosis (ICD-9 codes are provided in supple-
mental Table 1). Patients were excluded if they had unknown
demographic data or were younger than age 18 years, if they
developed CVD before DLBCL diagnosis, and if they had not
received chemotherapy for the DLBCL (supplemental Table 2).
The follow-up times for CVD continued until the first diagnosis of
a CVD event, non-cardiac death, or censor date, whichever was
earlier. We censored patients who remained alive and had not
developed CVD by the end of follow-up on 30 September 2019.
Follow-up started after the date of histologic lymphoma diagnosis
and ended 15 years after diagnosis. We counted the events only
if the diagnosis of CVD occurred beyond a landmark period of
9 months after lymphoma diagnosis because most patients have
completed the first-line treatment by that time. Because of the
heavily subsidized health care system in Hong Kong, patients with
chronic diseases and serious complications (eg, myocardial
infarction) are treated mostly in the Hong Kong Hospital Authority
public health care system.34 Therefore, the Hong Kong Hospital
Authority data should have captured nearly all hospital-managed
CVD outcomes with dates available.
Preexisting cardiovascular risk factors, comorbidities,
and other variables
The cardiovascular risk factors included hypertension, dyslipide-
mia, diabetes, chronic obstructive pulmonary disease (COPD),
alcohol-related diseases, atrial fibrillation, and history of depression
(supplemental Table 3).35,36 Diabetes, hypertension, and dyslipide-
mia were determined by using a combination of ICD-9 codes and
the prescriptions for medications for these conditions (supplemen-
tal Table 3). We used approaches similar to those adopted by
Poulsen et al37 to determine COPD, smoking status, and alcohol-
related diseases because these data were not directly available in
the CDARS. COPD and smoking status were captured by ICD-9
codes 491, 492, 496, and V15.82.37 We identified alcohol-related
diseases, which include hepatic and gastrointestinal diseases and
neurologic and psychiatric diseases (ICD-9 codes 291, 303, 305.0,
571, 980).37
We included sex and age at diagnosis. Comorbid conditions before
the lymphoma diagnosis were measured using the Royal College
of Surgeons (RCS) adaptation of the Charlson Comorbidity Index
(CCI).38 Overlapping cardiovascular risk factors were removed from
the overall RCS score. The remaining comorbidities in the CCI
(peripheral vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, rheumatic disease, liver disease,
hemiplegia/paraplegia, renal disease, and AIDS/HIV infection) were
combined into the score and examined as such. We extracted
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information regarding the need for medical fee waiver as a surrogate
for lower socioeconomic status.
Normal comparison group
The normal comparison group of people selected from a non-
cancer random sample without replacement from primary care
clinics were sex- and age-matched (within 3 years) to DLBCL
patients in a 5:1 ratio. The normal comparison group had no
previous diagnosis of cancer or CVD. Both the DLBCL and normal
comparison cohort have been retrieved from all 18 districts of
Hong Kong.
Treatment information
The treatment data included chemotherapy regimens (doxorubicin-
vs non-doxorubicin–based), rituximab, and the use of RT. The
absolute prescribed doses of doxorubicin were determined from
pharmacy records. The selected patients did not receive anthracy-
clines other than doxorubicin. Patients exposed to doxorubicin were
grouped according to the absolute cumulative doses (#500
or .500 mg, ;300 mg/m2, or 6 cycles of doxorubicin-based
treatment, assuming an average body surface area of 1.67 m2,
which is a reasonable number based on local data).39
Statistical analysis
Descriptive statistics for demographics, follow-up duration, and
prevalence of characteristics were generated for the DLBCL
survivors and normal comparison group. Continuous variables were
presented as medians with interquartile ranges and were compared
using rank-sum tests, whereas categorical variables were presented
as percentages and compared using x2 tests. To investigate
potential confounding by indication, we cross-tabulated preexisting
cardiovascular risk factors with receipt of doxorubicin and tested for
associations using x2 tests.
With the hypothesis that doxorubicin exposure drives the differ-
ences in CVD outcomes between groups, we used a cause-specific
hazard framework to deal with the competing risks of non-cardiac
mortality and to derive cause-specific hazard ratios (HRs).40,41
We evaluated the cause-specific cumulative incidence (csCI) of
CVD with levels of doxorubicin exposure using flexible parametric
competing risk analysis.42-45 We considered non-cardiac mortality
as a competing risk when comparing csCIs between lymphoma
survivors and the normal comparison group.42,43,46,47 The csCI of
CVD was derived after adjusting for age, sex, race, year of diagnosis,
need for medical fee waiver, cumulative dose of doxorubicin, receipt
of RT, rituximab administration, preexisting cardiovascular risk
factors (COPD or smoking, alcohol-related diseases, atrial fibrilla-
tion, hypertension, hyperlipidemia, dyslipidemia, diabetes mellitus,
and depression), use of aspirin, beta blockers, and angiotensin-
converting enzyme (ACE) inhibitors (supplemental Table 3), and
RCS comorbidity score. The csCIs of CVD for DLBCL patients and
the normal comparison group are illustrated by using cumulative
incidence plots. In secondary analyses, we included the csCI plots
of each CVD end point (ie, heart failure, cardiomyopathy, and
ischemic heart disease) for DLBCL patients and the normal
comparison group.We computed the ratios of predicted cumulative
incidence of lymphoma death and CVD among DLBCL patients at
5, 10, and 15 years and computed their respective 95% confidence
intervals (CIs) by bootstrapping. We performed a sensitivity
analysis to test whether the results were robust with respect to
the absence of landmark period and doxorubicin dose cutoff.
We used Stata v.16.1 (StataCorp, College Station, TX),
including the command stpm2 (version 1.7.4) to perform the
Excluded N = 1488:
Unknown demographic data or age 18
years N = 71
Patients with CVD diagnosed before
DLBCL N = 279



















Figure 1. Flowchart outlining the inclusion and exclusion
criteria (N 5 2600), Hong Kong, 2000-2018.
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statistical analyses and fit the flexible parametric survival
models.48,49
Results
The characteristics of the DLBCL cohort (N 5 2600) and the
normal comparison group (N5 13000) are detailed in Table 1. The
median age at diagnosis for the DLBCL cohort was 63 years
(interquartile range [IQR], 53-73 years) and 56.0% were male. As of
September 30, 2019, the median follow-up time from the index date
for the entire lymphoma survivor cohort was 6.8 years (IQR, 3.6-
10.5 years), providing 13 352 person-years of follow-up. Beyond
9 months from diagnosis, 118 (4.5%) of the DLBCL survivors
developed CVDs, with a median interval to CVD of 3.9 years (IQR,
1.8-6.0 years). Among DLBCL survivors, most deaths were a result
of lymphoma (53.8%), followed by pulmonary disorders (17.0%),
and infections (3.8%). Prescription of doxorubicin was associated
with age, cardiovascular risk factors, and social factors such that
patients who were older (odds ratio [OR] per 1-year increase in age,
0.96; 95% CI, 0.96-0.97; P , .001), had diabetes (OR, 0.70; 95%
CI, 0.57-0.86; P , .001), hypertension (OR, 0.73; 95% CI, 0.61-
0.88; P, .001), dyslipidemia or hyperlipidemia (OR, 0.69; 95% CI,
0.56-0.85; P , .001), ACE inhibitor use (OR, 0.74; 95% CI, 0.61-
0.92; P5 .005), or received medical fee waiver (OR, 0.61; 95% CI,
0.44-0.86; P 5 .004) were less commonly administered doxorubi-
cin. The median age of patients who received doxorubicin vs those
who did not was 57 vs 66 years, respectively (rank-sum test P ,
.001). Supplemental Table 4 provides the characteristics of patients
who received different regimens.
Those in the normal comparison group compared with DLBCL
survivors were significantly more likely to have hypertension (80.0%
vs 69.1%; P , .001), diabetes (36.2% vs 23.0%; P , .001),
dyslipidemia or hyperlipidemia (48.8% vs 22.5%; P, .001), anxiety
or depressive disorder (26.4% vs 16.8%; P , .001), be smokers
(43.6% vs 24.8%; P , .001), or require a medical fee waiver
(24.5% vs 7.7%; P , .001) (Table 1).
After multivariable adjustment (Table 2), patients treated with
.500 mg absolute dose of doxorubicin had an approximately
threefold increased risk of CVD compared with patients treated with
regimens that did not contain doxorubicin (adjusted cause-specific
HR, 2.55; 95% CI, 1.18-5.53; P5 .017). The cumulative incidence
curves reflected the results of the regression analysis. The patients
who had received .500 mg absolute dose of doxorubicin had 5-,
10- and 15-year csCIs of CVD of 8.0%, 11.1%, and 12.5%
respectively; the corresponding incidence rates for patients treated
with#500 mg were 4.2%, 6.0%, and 7.0%, respectively; and those
for patients treated with non-doxorubicin regimens, the correspond-
ing incidence rates were 3.8%, 5.6%, and 6.5%, respectively. The
incidence estimates for the normal comparison group were 3.1%,
4.4%, and 5.2%, respectively (Figure 2).
Aspirin use (HR, 4.63; 95% CI, 2.54-8.43; P, .001), ACE inhibitor
use (HR, 2.13; 95% CI, 1.32-3.42; P 5 .002), beta blocker use
(HR, 2.18; 95% CI, 2.54-8.43; P , .001), and hypertension (HR,
6.21; 95% CI, 0.80-48.43; P 5 .081) at baseline were also
associated with subsequent CVDs. Patients with preexisting
hypertension who used aspirin and who received .500 mg of
doxorubicin had 5-, 10-, and 15-year csCIs of CVD of 12.1%,
18.4%, and 21.1%, respectively (supplemental Figure 1).
The csCI plots of CVD end points (ie, heart failure/cardiomyopathy
and ischemic heart disease) for DLBCL patients and the normal
comparison group showed association between doxorubicin and
outcomes similar to those in the main analysis (Figure 3A-B). The
ratios of predicted cumulative incidence of lymphoma death and
CVD among DLBCL patients at 5, 10, and 15 years were 4.99
(95% CI, 4.95-5.03; P , .001), 3.48 (95% CI, 3.47-3.48; P ,
.001), and 3.08 (95% CI, 3.07-3.08; P , .001), respectively
(Figure 4). Repeated analyses with and without landmark periods
produced largely consistent results (Table 2; supplemental
Figure 2). Analysis of different cutoff doses of doxorubicin did not
change our main findings. We found that 42 lymphoma patients and
149 people from the normal comparison group had one of the major
autoimmune diseases (supplemental Table 3). A x2 test between
aspirin and major autoimmune diseases showed weak evidence of
association (P 5 .635).
Discussion
Our analysis of a contemporary cohort of 2600 patients diagnosed
with DLBCL without previous heart disease and 13 000 age-
and sex-matched normal comparison group (all derived from
a Hong Kong population electronic medical records database)
revealed an increased risk of cancer survivors developing CVDs,
despite their lower prevalence of underlying CVD risk factors
compared with the normal comparison group. Among the
patients with DLBCL, the receipt of a cumulative absolute
doxorubicin dose of 500 mg (;300 mg/m2) was associated with
a threefold increased risk of CVD compared with that for treatment
with non-doxorubicin regimens. We found that preexisting hyperten-
sion and aspirin use were associated with higher subsequent
risk of CVD. We hypothesize that history of aspirin on the
medication list is likely a surrogate for high cardiovascular risk.
This is a secondary finding supplementary to the main results
largely because of data sparsity and multiple comparisons in end
points. Aspirin could be prescribed for other medical conditions
such as autoimmune diseases. However, our sensitivity analysis
has revealed weak association between aspirin use and autoim-
mune diseases. The ratios of lymphoma death and CVD among
DLBCL patients decreased with time, implying that CVD might be
a larger health burden than lymphoma itself as follow-up time
increases.
The association between doxorubicin and cardiac risks is well-
established in the Western world. In patients with aggressive
non-Hodgkin lymphoma, a Surveillance, Epidemiology, and End
Results (SEER)-Medicare study that included 9438 patients
with DLBCL showed that doxorubicin, older age, presence of
comorbidity, hypertension, diabetes, preexisting atheroscle-
rotic disease, and preexisting heart disease were significantly
associated with subsequent risks of congestive heart failure
(CHF).18 A Danish registry study of 2508 non-Hodgkin lymphoma
survivors found that cumulative doxorubicin dose (per 100 mg/m2),
older age, male sex, prediagnosis CVD risk factors, and prediag-
nosis of intrinsic heart disease were significantly associated
with the risk of CHF.10 The authors also reported the 5-year
risks of CHF by age, sex, preexisting heart disease, and CVD
risk factors after a median follow-up time of 2.5 years.10 Unlike
in previous studies, our study excluded patients who did not
receive chemotherapy and those with preexisting cardiovas-
cular events, so that the very frail were excluded from our
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analysis. Despite our more stringent inclusion criteria, we
still detected significantly increased CVD risks among DLBCL
survivors; at a median follow-up of 6.8 years, the 10-year
estimated csCI of CVD was 18.4% in patients with cardiac
risk factors who had received .500 mg absolute dose of
doxorubicin.
In our selected study cohort, hypertension was the most prevalent
preexisting cardiac risk factor, and its presence was associated with
an estimated sixfold increased risk of subsequent CVD, although
the wide confidence interval reflects the limited power, and the
association could have been weakened because we included in the
model ACE inhibitors and beta blockers, which are commonly used






(n 5 13000) P
Lymphoma patients categorized by
CVD status (N 5 2600)
PCVD (n 5 175) No CVD (n 5 2425)
Patient factors
Median age at lymphoma diagnosis (IQR), y 63 (53-73) 63 (54-72) —* 70 (62-79) 62 (52-72) ,.001
Sex —* .875
Male 1456 (56.0) 7 280 (56.0) 99 (56.6) 1357 (56.0)
Female 1144 (44.0) 5 720 (44.0) 76 (43.4) 1068 (44.0)
Race/ethnicity .001 .068
Chinese 2484 (95.5) 12586 (96.8) 172 (98.3) 2312 (95.3)
Non-Chinese 116 (4.5) 414 (3.2) 3 (1.7) 113 (4.7)
RCS comorbidity scores ,.001 ,.001
0 1710 (65.8) 8 871 (68.2) 69 (39.4) 1641 (67.7)
1 664 (25.5) 2 631 (20.2) 61 (34.9) 603 (24.9)
$2 226 (8.7) 1 498 (11.5) 45 (25.7) 181 (7.5)
Median follow-up time for alive patients (IQR), y 6.8 (3.6-10.5) 7.8 (4.4-10.9) ,.001 5.3 (1.9-7.5) 6.9 (3.6-10.6) ,.001
Year of diagnosis — ,.001
2000-2004 398 (15.3) — 37 (21.1) 361 (14.9)
2005-2009 697 (26.8) — 68 (38.9) 629 (25.9)
2010-2014 870 (33.5) — 51 (29.1) 819 (33.8)
2015-2018 635 (24.4) — 19 (10.9) 616 (25.4)
Fee waiver recipients (surrogate for lower socioeconomic
status)
200 (7.7) 3 186 (24.5) ,.001 22 (12.6) 178 (7.3) .012
COPD or smoker 645 (24.8) 5 662 (43.6) ,.001 72 (41.1) 573 (23.6) ,.001
Alcohol-related diseases 18 (0.7) 98 (0.8) .739 0 (0.0) 18 (0.7) .253
Diabetes mellitus 598 (23.0) 4 708 (36.2) ,.001 71 (40.6) 527 (21.7) ,.001
Hypertension 1797 (69.1) 10393 (80.0) ,.001 173 (98.9) 1624 (67.0) ,.001
Dyslipidemia/hyperlipidemia 586 (22.5) 6 349 (48.8) ,.001 84 (48.0) 502 (20.7) ,.001
Anxiety or depressive disorders 436 (16.8) 3 435 (26.4) ,.001 37 (21.1) 399 (16.4) .109
Atrial fibrillation 31 (1.2) 514 (4.0) ,.001 7 (4.0) 24 (1.0) ,.001
ACE inhibitor use 574 (22.1) 5 269 (40.5) ,.001 102 (58.3) 472 (19.5) ,.001
Beta blocker use 792 (30.5) 5 436 (41.8) ,.001 119 (68.0) 673 (27.8) ,.001
Aspirin use 602 (23.2) 5 266 (40.5) ,.001 131 (74.9) 471 (19.4) ,.001
Treatment factors
Chemotherapy — — .761
Regimens containing doxorubicin
.500 mg 166 (6.4) — 13 (7.4) 153 (6.3)
#500 mg 699 (26.9) — 44 (25.2) 655 (27.0)
Non-doxorubicin regimens 1735 (66.7) — 118 (67.4) 1617 (66.7)
RT 308 (11.9) — — 25 (14.3) 283 (11.7) .301
Rituximab 1980 (76.2) — — 126 (72.0) 49 (28.0) .182
All data are no. (%) unless otherwise indicated.
*People in the normal comparison group were sex- and age-matched to lymphoma patients.
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for hypertension. Anthracyclines can induce abnormal cell signaling
and cytotoxic molecules that are in common with those produced
by hypertension.50,51 The resultant oxidative stress and inflamma-
tory processes induce damage to the cardiovascular system.51 Our
finding is consistent with the pathophysiology that hypertension can
exacerbate the cardiotoxic effects of doxorubicin.50 The most prevalent
CVD risk factor in Asia is hypertension.52 Therefore, Asian countries
are faced with the challenge of large numbers of hypertensive patients
who also have very low awareness of this silent risk factor and a history
of low rates of blood pressure control.52-54 Our findings underscore
the importance of tailoring DLBCL treatment decisions on the basis of
population-specific data and the prevalence of preexisting cardiac risk
factors, including a history of hypertension and/or other cardiovascular
risk factors. This suggests that aggressive control of blood pressure
and close follow-up of DLBCL survivors after exposure to doxorubicin
maybe more clinically important.
For posttreatment cardiac surveillance, the American Society of
Clinical Oncology Clinical Practice Guidelines recommend that an
echocardiogram be performed between 6 and 12 months after
completion of cancer-directed therapy in asymptomatic patients at
increased risk of cardiac dysfunction.55 The European Society of
Medical Oncology recommends consideration of left ventricular
ejection fraction assessment at 6 to 12 months and possibly 2 years
posttreatment, as well as periodic reassessment thereafter in
asymptomatic patients with normal baseline ejection fraction after
anthracycline-based chemotherapy.56 Cardiology authorities have
also published guidelines on monitoring after anthracyclines. They
recommended a more frequent assessment of cardiac function57,58:
document baseline left ventricular ejection fraction, repeat
measurement after doxorubicin dose reaches 240 mg/m2, and
repeat measurement for each additional 50 mg/m2, then reassess
6 months after completing therapy. Our finding that most CVDs
Table 2. Cause-specific HRs for new-onset cardiovascular disease among patients with DLBCL from unadjusted and adjusted analyses
including with and without 9-mo landmark period (N 5 2600) in Hong Kong, 2000-2018
Characteristic*











Doxorubicin #500 mg vs
non-doxorubicin regimen
0.86 (0.61-1.22) .405 0.98 (0.66-1.44) .902 0.89 (0.59-1.36) .599 1.21 (0.75-1.94) .437
Doxorubicin .500 mg vs
non-doxorubicin regimen
1.03 (0.58-1.82) .927 1.43 (0.76-2.71) .270 1.16 (0.60-2.25) .651 2.55 (1.18-5.53) .017
Receipt of RT 1.24 (0.80-1.90) .333 0.81 (0.47-1.41) .464 1.07 (0.61-1.87) .805 0.59 (0.30-1.15) .120
Rituximab 0.82 (0.58-1.14) .244 0.60 (0.39-0.93) .023 0.81 (0.54-1.21) .302 0.68 (0.41-1.15) .154
Patient factors
Age at lymphoma diagnosis
(per 1-y increase)
1.05 (1.04-1.06) ,.001 1.01 (1.00-1.03) .138 1.05 (1.04-1.06) ,.001 1.01 (0.99-1.03) .409
Sex (male vs female) 1.15 (0.85-1.56) .350 1.08 (076-1.54) .645 1.12 (0.78-1.61) .536 1.01 (0.66-1.55) .966
RCS comorbidity score‡
1 vs 0 2.49 (1.76-3.52) ,.001 1.16 (0.77-1.76) .473 2.41 (1.57-3.70) ,.001 1.11 (0.67-1.83) .687
2 vs 0 5.24 (3.59-7.66) ,.001 1.01 (0.59-1.72) .967 5.86 (3.75-9.17) ,.001 0.99 (0.53-1.94) .974
Year of diagnosis
2005-2009 vs 2000-2004 1.16 (0.77-1.75) .471 1.16 (0.72-1.89) .540 1.02 (0.64-1.62) .921 1.03 (0.60-1.76) .917
2010-2014 vs 2000-2004 0.83 (0.53-1.28) .396 0.92 (0.52-1.64) .776 0.76 (0.45-1.26) .281 0.76 (0.40-1.44) .400
2015-2018 vs 2000-2004 0.70 (0.39-1.24) .221 1.08 (0.54-2.16) .823 0.20 (0.06-0.67) .009 0.28 (0.07-1.10) .068
Fee waiver recipients (surrogate for lower
socioeconomic status)
1.74 (1.11-2.72) .015 1.12 (0.66-1.90) .661 1.84 (1.09-3.13) .023 1.14 (0.62-2.11) .675
COPD or smoker 1.94 (1.43-2.63) ,.001 1.27 (0.89-1.81) .192 2.12 (1.48-3.05) ,.001 1.32 (0.86-2.02) .203
Diabetes mellitus 2.65 (1.96-3.59) ,.001 1.16 (0.79-1.72) .442 2.36 (1.62-3.43) ,.001 0.85 (0.53-1.36) .495
Hypertension 46.70 (11.58-188.25) ,.001 6.62 (1.45-30.10) .014 68.14 (9.52-487.82) ,.001 6.21 (0.80-48.43) .081
Dyslipidemia/hyperlipidemia 2.86 (2.12-3.86) ,.001 1.01 (0.71-1.44) .953 3.28 (2.29-4.71) ,.001 1.18 (0.77-1.82) .444
Anxiety or depressive disorders 1.38 (0.96-1.98) .085 0.98 (0.66-1.47) .941 1.36 (0.88-2.12) .167 0.90 (0.56-1.43) .650
ACE inhibitor use 5.24 (3.87-7.09) ,.001 1.95 (1.30-2.93) .001 5.52 (3.82-7.97) ,.001 2.13 (1.32-3.42) .002
Beta blocker use 5.14 (3.74-7.07) ,.001 1.66 (1.12-2.44) .011 7.07 (4.69-10.65) ,.001 2.18 (1.32-3.60) .002
Aspirin use 9.71 (6.90-13.67) ,.001 4.35 (2.80-6.76) ,.001 11.60 (7.51-17.93) ,.001 4.63 (2.54-8.43) ,.001
*Race, alcohol-related diseases, and atrial fibrillation were not adjusted in the model because most of the patients were Hong Kong Chinese and too few patients had alcohol-related
diseases and atrial fibrillation.
†Cause-specific HRs by competing risk analyses.
‡Included peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, liver disease, hemiplegia/paraplegia, renal disease, AIDS/HIV
infection.
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developed within the first few years after treatment (median, ;4
years) supports these recommendations of cardiac evaluation early
posttreatment. Implementation of such stringent risk stratifications
and early frequent cardiac assessment could have potentially
allowed earlier detection of some of the cardiotoxicities and
potentially the ability to prevent CVD events in the future. We
propose that the follow-up of patients in this period by oncologists
and primary care physicians should focus not only on disease
relapse but also on the evaluation for and prompt treatment of
cardiac risk factors, with cardiac screening of asymptomatic
patients.
Our study has several limitations. The data were subject to























DLBCL survivors with no doxorubicin exposure
DLBCL survivors with 500mg doxorubicin
DLBCL survivors with 500mg doxorubicin
Normal comparison group
Figure 2. csCIs of cardiovascular diseases for DLBCL survivors,
Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated
by levels of exposure to doxorubicin (N 5 2600) and in the normal

















































DLBCL survivors with no doxorubicin exposure
DLBCL survivors with 500mg doxorubicin
DLBCL survivors with 500mg doxorubicin
Normal comparison group
B
Figure 3. csCIs of ischemic heart disease, heart failure, and cardiomyopathy for DLBCL survivors, Hong Kong, 2000-2018. csCIs of ischemic heart disease (A)
and heart failure and cardiomyopathy (B) were estimated by levels of exposure to doxorubicin (N 5 2600) and in normal comparison group (N 5 13000) with non-cardiac
death as competing risk.
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medical conditions not measurable by our methodology may have
been less likely to receive doxorubicin-containing regimens. In our
determination of outcome events, we restricted the primary outcome
to CVD diagnosed at a hospital or death to conservatively capture the
symptomatic and most severe cases.59 This suggests that our study
might underestimate the true incidence of cardiotoxicity by not
capturing milder forms of CVD events. However, this can avoid
misclassification as a result of coding errors and uncertainty in the
diagnosis of milder CVD events. Previous studies have demonstrated
high sensitivity and specificity in diagnosis and medication code
retrieval from CDARS.27,28 It is likely that we would have captured the
majority of the CVDs diagnosed at the hospital and death, given our
public health care system.34 In addition, the registry database lacks
detailed information on lymphoma and its treatment, including the
stage at diagnosis, body surface area, and RT site and dose. Similar
to other studies of electronic medical record databases, our study
also lacked data on important lifestyle factors such as physical activity
level and diet, which are known to have an impact on the onset of
CVD. Although these limitations tend to bias our estimates toward the
null, we still detected important associations between doxorubicin
and cardiovascular risk factors and risk of CVD. Despite these
limitations, our study has several strengths.We analyzed a reasonably
large and homogeneous cohort in Hong Kong. Some studies used
claims data or the number of cycles as surrogate estimates for
chemotherapy dose.10,18,60 However, chemotherapy dose reduc-
tions are common, especially in elderly patients older than age
75 years.60-63 In a study of US veterans, only 14% of patients age
80 years or older who received doxorubicin completed treatment
at $85% dose intensity.62 We described the magnitude of CVD
risks segregated by actual doxorubicin dose levels among patients
with DLBCL who received chemotherapy as part of anticancer
treatment. Hequet et al11 reported that subclinical cardiomyopa-
thy was more common than clinically overt cardiomyopathy.
Although we used diagnosis codes to identify outcome events,
we avoided overdiagnosis by using only inpatient codes that
generally indicated greater severity, thereby reducing the risk of
misclassification.
This study demonstrated for the first time that doxorubicin
contributed to excess cardiotoxicity in a dose-related manner in
a Hong Kong population of patients with DLBCL without preexisting
CVD. In addition, hypertension, an often under-recognized and
undertreated condition rampant among Asian patients,52 was
associated with an increased trend of therapy-related CVD. We
also found that many incident CVDs in our study occurred soon
after lymphoma treatment. Together, these findings highlight the
importance of pretreatment screening for CVD risk factors, careful
balancing of the risks and benefits of treatment decisions, rigorous
monitoring of cardiac function, and early cardiac screening and
intervention to minimize the risk of CVD during and after lymphoma
treatment and throughout cancer survivorship.
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